0001626199-21-000130.txt : 20210927 0001626199-21-000130.hdr.sgml : 20210927 20210927070220 ACCESSION NUMBER: 0001626199-21-000130 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210923 FILED AS OF DATE: 20210927 DATE AS OF CHANGE: 20210927 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CONWAY ROBERT E CENTRAL INDEX KEY: 0001184334 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37449 FILM NUMBER: 211278983 MAIL ADDRESS: STREET 1: C/O ARCA BIOPHARMA, INC STREET 2: 8001 ARISTA PLACE, STE 430 CITY: BROOMFIELD STATE: CO ZIP: 80021 FORMER NAME: FORMER CONFORMED NAME: CONWAY ROBERT DATE OF NAME CHANGE: 20020829 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC. CENTRAL INDEX KEY: 0001626199 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208969493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-788-4545 MAIL ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Nivalis Therapeutics, Inc. DATE OF NAME CHANGE: 20150211 FORMER COMPANY: FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141121 4/A 1 wf-form4a_163274052780471.xml FORM 4/A X0306 4/A 2021-09-23 2021-09-24 0 0001626199 ALPINE IMMUNE SCIENCES, INC. ALPN 0001184334 CONWAY ROBERT E C/O ALPINE IMMUNE SCIENCES, INC. 188 EAST BLAINE STREET, SUITE 200 SEATTLE WA 98102 1 0 0 0 Common Stock 2021-09-23 4 P 0 15000 10.0769 A 50000 I By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust The Form 4 filed on September 24, 2021 inadvertently included an incorrect transaction code for the reported transaction. The transaction code included on the original Form 4 was "S" while the correct transaction code should have been "P". This transaction was executed in multiple trades at prices ranging from $9.945 to $10.20. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. /s/ James Paul Rickey, attorney-in-fact 2021-09-27